Treatment with apalutamide (Erleada) resulted in a rapid and substantial decline in PSA, and greater magnitude of PSA decline correlated with improvement in several oncologic endpoints, results from the phase III SPARTAN study showed.
A study investigating associations between statin use and prostate cancer outcomes provides further evidence that the medication may have race-related benefit, providing protective effects among Caucasian men but not in African-Americans.
Studies show moderate alcohol intake has surprising links to prostate disease.
"While these results cannot be extrapolated to men with very high PSA level or advanced clinical stage, the study provides appropriate benchmark data for our contemporary patients with high-risk clinically localized prostate cancer," writes Badar M. Mian, MD.
Men with AR-V7-positive prostate cancer seem to respond positively to a combination therapy with ipilimumab (Yervoy) and nivolumab (Opdivo).
Researchers studied data from a racially diverse cohort of 650 men undergoing a prostate biopsy between January 2007 and January 2018.
Other pipeline products discussed in this round-up include agents for metastatic urothelial cancer, clear cell renal cell carcinoma, and stress urinary incontinence.
Radical prostatectomy can provide superior survival compared with radiation therapy, especially in young and healthy men.
Personally tailored intervention generates patient interest, QoL improvements.
Benefit evident regardless of metastasis site, phase III analysis shows.